Post-operative atrial fibrillation was once viewed as a fairly insignificant issue, but more recent research suggests it can increase a patient’s risk of multiple adverse events. 

Samir Kapadia, MD, chair of the department of cardiovascular medicine at Cleveland Clinic, shared his perspective on the use of cerebral protection devices during TAVR procedures. 

A new study published in JACC: Heart Failure offers more evidence that a patient's feelings can strongly influence their risk of poor cardiovascular health. 

The team hopes its findings can lead to significant progress in the war against fatty plaques.

Both devices were approved for treating significant heart rhythm issues. 

Fuster, one of the world’s most prominent cardiologists, said the award was a "great honor," especially since he was born in Barcelona. 

It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device. 

Whatever specific shape work takes in the near and distant future, it’s likely the COVID-19 era will be looked back upon as a before-and-after dividing line.

The drops were linked to 55 reports of adverse events, including eye infections, permanent loss of vision and one death with a bloodstream infection.